Genetic Mutation Assay in Ovarian Cancer Patient
Danastri Tiara Cintantya1, and Willy Sandhika2,3*
Abstract
Ovarian cancer is the third most common cases of cancer among Indonesian women. It has a poor prognosis with a moderate to low 5-year survival rate with conventional therapy. Targeted therapies, immunotherapies, and novel treatment approaches are being explored in clinical trials, offering potential improvements in survival rates and outcomes, unfortunately, not every patient responds to these therapeutic modalities. It takes a molecular assay to predict which patient has a response to this therapy. Genome instability is one of the unique characteristics found in most cancers in humans. Ovarian cancer patients with mutations of BRCA1 or BRCA2, have been found to exhibit high sensitivity to PARP inhibitor therapy. Targeting the Homologous Recombinant Deficiency (HRD) that was caused by BRCA mutations and inhibiting PARP-mediated DNA repair, would result in the death of cancer cells. Conclusion: molecular assay from ovarian cancer tissue would have the benefit to predict response to PARP inhibitor targeted therapy.
Keywords
cancer; ovarian cancer; BRCA mutation; homologous recombinant deficiency
Cite This Article
Cintantya, D. T., Sandhika, W. (2023). Genetic Mutation Assay in Ovarian Cancer Patient. International Journal of Scientific Advances (IJSCIA), Volume 4| Issue 4: Jul-Aug 2023, Pages 619-622, URL: https://www.ijscia.com/wp-content/uploads/2023/08/Volume4-Issue4-Jul-Aug-No.482-619-622.pdf
Volume 4 | Issue 4: Jul-Aug 2023
